vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 16.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
ESPR vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $205.4M |
| Net Profit | — | $816.0K |
| Gross Margin | — | 12.4% |
| Operating Margin | 50.6% | 3.3% |
| Net Margin | — | 0.4% |
| Revenue YoY | 143.7% | 16.6% |
| Net Profit YoY | — | 113.1% |
| EPS (diluted) | $0.32 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $205.4M | ||
| Q2 25 | $82.4M | $191.5M | ||
| Q1 25 | $65.0M | $201.6M | ||
| Q4 24 | $69.1M | $193.9M | ||
| Q3 24 | $51.6M | $175.9M | ||
| Q2 24 | $73.8M | $169.5M | ||
| Q1 24 | $137.7M | $184.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $816.0K | ||
| Q2 25 | $-12.7M | $4.4M | ||
| Q1 25 | $-40.5M | $4.8M | ||
| Q4 24 | — | $-8.7M | ||
| Q3 24 | $-29.5M | $-6.2M | ||
| Q2 24 | $-61.9M | $-5.3M | ||
| Q1 24 | $61.0M | $2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 12.4% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 13.0% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 16.8% |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | 3.3% | ||
| Q2 25 | 8.6% | 5.5% | ||
| Q1 25 | -34.0% | 5.2% | ||
| Q4 24 | -6.4% | 1.4% | ||
| Q3 24 | -31.0% | 0.5% | ||
| Q2 24 | 3.5% | 1.2% | ||
| Q1 24 | 52.5% | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 0.4% | ||
| Q2 25 | -15.4% | 2.3% | ||
| Q1 25 | -62.2% | 2.4% | ||
| Q4 24 | — | -4.5% | ||
| Q3 24 | -57.2% | -3.5% | ||
| Q2 24 | -83.9% | -3.1% | ||
| Q1 24 | 44.3% | 1.6% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $0.01 | ||
| Q2 25 | $-0.06 | $0.03 | ||
| Q1 25 | $-0.21 | $0.04 | ||
| Q4 24 | $-0.14 | $-0.08 | ||
| Q3 24 | $-0.15 | $-0.05 | ||
| Q2 24 | $-0.33 | $-0.04 | ||
| Q1 24 | $0.34 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $2.2M |
| Total DebtLower is stronger | — | $250.8M |
| Stockholders' EquityBook value | $-302.0M | $162.8M |
| Total Assets | $465.9M | $694.1M |
| Debt / EquityLower = less leverage | — | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | $2.2M | ||
| Q2 25 | $86.1M | $2.2M | ||
| Q1 25 | $114.6M | $2.3M | ||
| Q4 24 | $144.8M | $1.6M | ||
| Q3 24 | $144.7M | $2.9M | ||
| Q2 24 | $189.3M | $3.2M | ||
| Q1 24 | $226.6M | $1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $250.8M | ||
| Q2 25 | — | $263.3M | ||
| Q1 25 | — | $260.6M | ||
| Q4 24 | — | $265.2M | ||
| Q3 24 | — | $289.9M | ||
| Q2 24 | — | $303.1M | ||
| Q1 24 | — | $258.8M |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $162.8M | ||
| Q2 25 | $-433.5M | $159.8M | ||
| Q1 25 | $-426.2M | $154.8M | ||
| Q4 24 | $-388.7M | $148.6M | ||
| Q3 24 | $-370.2M | $155.0M | ||
| Q2 24 | $-344.2M | $158.8M | ||
| Q1 24 | $-294.3M | $163.6M |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $694.1M | ||
| Q2 25 | $347.1M | $704.9M | ||
| Q1 25 | $324.0M | $690.7M | ||
| Q4 24 | $343.8M | $668.5M | ||
| Q3 24 | $314.1M | $699.3M | ||
| Q2 24 | $352.3M | $704.7M | ||
| Q1 24 | $373.1M | $671.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.68× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | — | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $16.3M |
| Free Cash FlowOCF − Capex | — | $12.1M |
| FCF MarginFCF / Revenue | — | 5.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | — | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $16.3M | ||
| Q2 25 | $-31.4M | $-4.5M | ||
| Q1 25 | $-22.6M | $22.3M | ||
| Q4 24 | $-35.0M | $33.1M | ||
| Q3 24 | $-35.3M | $17.2M | ||
| Q2 24 | $-7.2M | $-5.6M | ||
| Q1 24 | $53.8M | $5.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $12.1M | ||
| Q2 25 | — | $-9.2M | ||
| Q1 25 | — | $9.5M | ||
| Q4 24 | — | $24.0M | ||
| Q3 24 | $-35.5M | $11.7M | ||
| Q2 24 | $-7.3M | $-15.3M | ||
| Q1 24 | $53.8M | $-2.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | -4.8% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | -68.7% | 6.6% | ||
| Q2 24 | -9.9% | -9.0% | ||
| Q1 24 | 39.0% | -1.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 6.3% | ||
| Q4 24 | 0.0% | 4.7% | ||
| Q3 24 | 0.3% | 3.2% | ||
| Q2 24 | 0.1% | 5.7% | ||
| Q1 24 | 0.1% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 20.03× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 4.63× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
